The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.

MLA

Han, Chanhee, et al. “The Poly (ADP-Ribose) Polymerase Inhibitor Olaparib and Pan-ErbB Inhibitor Neratinib Are Highly Synergistic in HER2 Overexpressing Epithelial Ovarian Carcinoma in Vitro and in Vivo.” Gynecologic Oncology, vol. 170, Mar. 2023, pp. 172–78. EBSCOhost, https://doi.org/10.1016/j.ygyno.2023.01.015.

APA

Han, C., McNamara, B., Bellone, S., Harold, J., Manara, P., Hartwich, T. M. P., Mutlu, L., Yang-Hartwich, Y., Zipponi, M., Demirkiran, C., Verzosa, M. S. Z., Altwerger, G., Ratner, E., Huang, G. S., Clark, M., Andikyan, V., Azodi, M., Dottino, P. R., Schwartz, P. E., & Santin, A. D. (2023). The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology, 170, 172–178. https://doi.org/10.1016/j.ygyno.2023.01.015

Chicago

Han, Chanhee, Blair McNamara, Stefania Bellone, Justin Harold, Paola Manara, Tobias Max Philipp Hartwich, Levent Mutlu, et al. 2023. “The Poly (ADP-Ribose) Polymerase Inhibitor Olaparib and Pan-ErbB Inhibitor Neratinib Are Highly Synergistic in HER2 Overexpressing Epithelial Ovarian Carcinoma in Vitro and in Vivo.” Gynecologic Oncology 170 (March): 172–78. doi:10.1016/j.ygyno.2023.01.015.